ClinicalTrials.gg
Not yet recruitingNCT07951216MOMENTUMUpdated Nov 20, 2026

Role of Uremic Toxins in Mild Cognitive Impairment in Chronic Kidney Disease

An interventional study of MoCA Test and Laboratory tests in Chronic Kidney Disease, sponsored by Mario Negri Institute for Pharmacological Research. Not yet recruiting at 5 sites in 4 countries. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Mario Negri Institute for Pharmacological Research · Not applicable, Interventional, and Other

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Renal Insufficiency, Chronic by Mario Negri Institute for Pharmacological Research — 3 open to participants now, 4 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Mario Negri Institute for Pharmacological Research.

Started
2027
the only one that year
No phase
3 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Renal Insufficiency, Chronic by Mario Negri Institute for Pharmacological Research, this one is the only one that started in 2027, is one of 3 with no phase, and was the 10th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 699 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

3 of the 10 studies in Renal Insufficiency, Chronic by Mario Negri Institute for Pharmacological Research are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Renal Insufficiency, Chronic by Mario Negri Institute for Pharmacological Research, or all of them as a file.
02

Study summary

MOMENTUM is an investigator-initiated, multicentre, international, controlled, cross-sectional and longitudinal clinical study, which aims to evaluate the association between plasma levels of UTs and the presence and severity of cognitive impairment, and their mechanistic interplay in study participants with CKD at different disease stages.

The study consists of three main phases: a screening period, a cross-sectional (baseline) phase, and an 18-month follow-up (longitudinal phase).

Read the detailed description

Chronic kidney disease (CKD) represents a major and growing global health challenge, affecting over 800 million people worldwide across stages. Its prevalence is increasing due to rising rates of diabetes, hypertension, and obesity, the most common causes of CKD, and the disease is projected to become the fifth leading cause of death by 2040. CKD has been recently prioritized within the WHO noncommunicable diseases agenda in alignment with the United Nation's Sustainable Development Goal (SDG) 3.4 and 3.8. Beyond its direct contribution to morbidity and mortality and its established role as a major risk factor for cardiovascular disease, CKD also significantly impacts neurological health.

Cognitive impairment - particularly Mild Cognitive Impairment (MCI) - is increasingly recognized as a frequent but underexplored complication, occurring at more than twice the rate observed in age-matched individuals from the general population. MCI markedly increases the risk of progression to dementia, and is associated with substantial consequences for patients, caregivers, healthcare systems, and society, highlighting the importance of early identification and intervention.

Despite its clinical and societal importance, MCI-CKD remains an under-recognized health challenge. Its pathophysiological mechanisms are poorly understood, no specific biomarkers have been validated to support diagnosis or prognosis, and no established guidelines exist for its systematic monitoring or management. Most patients remain unaware of the condition, and healthcare providers often overlook it. This lack of awareness and diagnostic capacity hampers timely interventions, including referrals for symptomatic treatments, cognitive rehabilitation strategies, or preventive measures.

As a transitional stage preceding clinical dementia, early identification of MCI-CKD may allow nephrologists to refer patients to neurologists for symptomatic treatments and cognitive rehabilitation strategies.18 Patients diagnosed with MCI-CKD may also be referred for other interventions addressing other modifiable drivers of MCI, such as sleep, stress, dietary habits, exercise and cardiovascular disease.

Clinically, CKD is characterized by a progressive decline in kidney function, typically assessed by the glomerular filtration rate (GFR), which can be estimated through equations based on serum creatinine, cystatin C, or a combination of both (eGFR), or directly measured using exogenous filtration markers such as iohexol or iothalamate clearance (mGFR). Additional indicators of kidney damage include blood urea nitrogen (BUN) levels, the urinary albumin-to-creatinine ratio (ACR), and histological findings from kidney biopsy. However, accurately quantifying nephron loss and the extent of renal fibrosis remains challenging. As kidney function declines, disturbances develop in electrolyte, water, acid-base, and mineral homeostasis. Uremic toxins (UTs) accumulate, and renal anaemia emerges. Several CKD-related factors, including metabolic alterations, inflammation, vascular dysfunction, and UT accumulation, have been independently associated with an increased risk of cognitive impairment.

The MOMENTUM cross-sectional and longitudinal clinical study is designed to address this critical gap. By comprehensively characterizing cognitive impairment in CKD and integrating multimodal biomarkers, including circulating and microbiome-derived uremic toxins, advanced neuroimaging, and clinical assessments, it aims to improve early detection and risk stratification of MCI-CKD. This knowledge will contribute to a better understanding of disease mechanisms, support earlier diagnosis, and enable the development of targeted strategies to reduce cognitive decline and dementia burden in individuals with CKD.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Cognitive impairment
  • Chronic Kidney Disease
  • Uremic Toxins
  • Blood Brain Barrier
  • Gut Microbiome
  • Brain MRI
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 40-75 years at time of screening;
  • Availability for longitudinal follow-up;
  • Signed

Specifically for CKD participants:

  • CKD stage G3a/G3b, or stage G4-G5 without kidney replacement therapy, or stage G5 undergoing hemodialysis (HD) for more than 3 months;
  • score in the range [18-25];41

Specifically for controls:

  • Normal renal function:

    • For controls aged \< 65 years, ≥ 90 mL/min/1.73 m2;
    • For controls aged ≥ 65 years, eGFR ≥ 60 mL/min/1.73 m2.
  • No detectable proteinuria at screening (negative urine dipstick);
  • MoCA score ≥ 26/30.

Exclusion criteria

Exclusion Criteria

  • to MRI including claustrophobia, pregnancy or breastfeeding, cardiac pacemakers, aneurysm clips, or other MRI-incompatible devices, or inability to undergo MRI;
  • Pre-existing neurological disorders known to affect cognitive function (e.g., dementia, Parkinson's disease, multiple sclerosis, epilepsy or neurodegenerative disorders);
  • History of ischemic or hemorrhagic stroke and/or previous brain surgery;
  • History of severe traumatic brain injury;
  • Treated or untreated depressive disorder that, in the investigator's judgment, may interfere with cognitive assessment;
  • Recent hospitalization for acute events within the last 3 months, except for percutaneous transluminal angioplasty (PTA) of fistula, catheter replacement and elective hospitalizations;
  • Serious acute illness within the last 3 months;
  • Active solid tumors with or without ;
  • Inflammatory bowel disease;
  • Systemic treatment for > 6 months at a prednisone-equivalent dose > 10 mg/day;
  • Planned pregnancy during the 18-month follow-up period;

Specifically for CKD patients:

  • Peritoneal dialysis;
  • Kidney transplantation at enrolment;

Specifically for controls:

● Any chronic clinically significant condition, except for hypertension treated with \< 3 antihypertensive drugs.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Group 1

    Patients with CKD stage G3 (eGFR 30-59 mL/min/1.73 m2), balanced between the two sub-stages G3a (eGFR 45-59 mL/min/1.73 m2) and G3b (eGFR 30-44 mL/min/1.73 m2)

    Behavioral: MoCA Test · Diagnostic Test: Laboratory tests · Diagnostic Test: Non-contrast-enhanced brain MRI · Behavioral: Comprehensive neuropsychological test battery · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections · Behavioral: Questionnaires · Behavioral: New MCI-CKD QoL Questionnaire

  • Experimental
    Group 2

    Patients with CKD stages G4-G5 without kidney replacement therapy (eGFR \< 30 mL/min/1.73 m2)

    Behavioral: MoCA Test · Diagnostic Test: Laboratory tests · Diagnostic Test: Non-contrast-enhanced brain MRI · Behavioral: Comprehensive neuropsychological test battery · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections · Behavioral: Questionnaires · Behavioral: New MCI-CKD QoL Questionnaire

  • Experimental
    Group 3

    Patients with CKD stage G5 on chronic hemodialysis (eGFR \< 15 mL/min/1.73 m2)

    Behavioral: MoCA Test · Diagnostic Test: Laboratory tests · Diagnostic Test: Non-contrast-enhanced brain MRI · Behavioral: Comprehensive neuropsychological test battery · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections · Behavioral: Questionnaires · Behavioral: New MCI-CKD QoL Questionnaire

  • Experimental
    Group 4

    Healthy controls

    Behavioral: MoCA Test · Diagnostic Test: Laboratory tests · Diagnostic Test: Non-contrast-enhanced brain MRI · Behavioral: Comprehensive neuropsychological test battery · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section · Behavioral: Questionnaires

Interventions

  • BehavioralMoCA Test

    Montreal Cognitive Assessment Test

  • Diagnostic testLaboratory tests

    The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling

  • Diagnostic testNon-contrast-enhanced brain MRI

    MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI)

  • BehavioralComprehensive neuropsychological test battery

    The comprehensive battery of neuropsychological tests includes: Episodic memory \[assessed through Rey Auditory Verbal Learning Test (RAVLT)\]; Processing speed and executive function \[assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)\]; Processing speed, attention, and working memory \[assessed through Symbol Digit Modalities Test (SDMT)\]; Language and executive function \[assessed through Verbal Fluency Test (VFT))\] Executive function assessed through Frontal Assessment Battery (FAB)\]

  • BehavioralKidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section

    "Your Health" section, corresponding to the SF-12 questionnaire

  • BehavioralKidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections

    Sections specific to kidney disease excluding the first section

  • BehavioralQuestionnaires

    Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS).

  • BehavioralNew MCI-CKD QoL Questionnaire

    The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project

06

What researchers measure

Primary outcomes

  1. Correlation between blood levels of the 6 predefined UTs (individually and in combination) and the presence and severity of cognitive impairment, within each CKD group separately.

    Correlation coefficient (e.g., Pearson's r or Spearman's rho). The coefficient is computed for each of the 6 UTs and for the combination, within each CKD group separately.

    Time frame: Baseline (Visit 2, Day 0)

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Dec 2029, 32 months later.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 32 months is above that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Apr 1, 2027
Primary completionEst.
Dec 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951216
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Apr 1, 2027 (estimated)
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Matias Trillini, M.D.
Contact
matias.trillini@marionegri.it
+390354535411
Norberto Perico, M.D.
study director · Istituto Di Ricerche Farmacologiche Mario Negri

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion